Biogen (NASDAQ:BIIB) Shares Gap Down – Here’s Why

Biogen Inc. (NASDAQ:BIIB) shares gapped down before the market opened on Tuesday . The stock had previously closed at $187.57, but opened at $179.46. Biogen shares last traded at $179.6680, with a volume of 410,474 shares trading hands.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: FDA approves a higher‑dose SPINRAZA regimen, broadening Biogen’s commercial opportunity in spinal muscular atrophy and supporting longer‑term rare‑disease revenue. This approval reinforces Biogen’s existing franchise and was cited as a near‑term positive driver for the stock. FDA SPINRAZA Approval
• Neutral Sentiment: Analysts largely kept Hold/neutral ratings and existing price targets after the Spinraza approval and incremental pipeline updates, signaling that the approval helps but does not meaningfully change consensus expectations. That keeps analyst guidance mixed for now. Analyst Reaction
• Negative Sentiment: Biogen agreed to acquire Apellis Pharmaceuticals for roughly $5.6B in cash ($41/ share plus contingent value payments), which unlocks empaveli and syfovre assets and accelerates an entry into nephrology — but the deal carries a material premium, near‑term cash outflow and integration risk. Investors appear concerned about the near‑term EPS/financial impact and capital deployment, which likely pressured BIIB despite the strategic rationale. Apellis Acquisition

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Morgan Stanley set a $190.00 price target on Biogen in a report on Sunday, February 8th. TD Cowen upped their target price on Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Guggenheim raised their target price on Biogen from $185.00 to $246.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Canaccord Genuity Group lifted their price target on shares of Biogen from $220.00 to $230.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Finally, Tudor Pickering set a $201.00 price objective on shares of Biogen in a research note on Monday, February 9th. Twelve equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $205.31.

Biogen Trading Down 4.4%

The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The business’s fifty day moving average is $185.83 and its two-hundred day moving average is $170.70. The firm has a market cap of $26.31 billion, a price-to-earnings ratio of 20.35, a price-to-earnings-growth ratio of 1.46 and a beta of 0.15.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same period in the previous year, the business posted $3.44 EPS. The company’s quarterly revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Equities analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Insider Buying and Selling at Biogen

In other Biogen news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the transaction, the insider owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.18% of the stock is owned by company insiders.

Institutional Trading of Biogen

A number of hedge funds and other institutional investors have recently made changes to their positions in BIIB. Convergence Investment Partners LLC acquired a new position in shares of Biogen during the 3rd quarter worth approximately $1,342,000. Caprock Group LLC acquired a new stake in Biogen during the 3rd quarter valued at $742,000. Pitcairn Co. acquired a new stake in Biogen during the 2nd quarter valued at $936,000. Fluent Financial LLC bought a new position in Biogen during the third quarter worth $3,578,000. Finally, Leuthold Group LLC acquired a new position in shares of Biogen in the third quarter valued at $3,294,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.